Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis.
ESR1
digital PCR
liquid biopsy
metastasized breast cancer
next-generation sequencing
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
05
2023
accepted:
28
07
2023
medline:
7
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
epublish
Résumé
Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
Identifiants
pubmed: 37675216
doi: 10.3389/fonc.2023.1221773
pmc: PMC10477975
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1221773Informations de copyright
Copyright © 2023 Najim, Papadimitriou, Broeckx, Huizing and Tjalma.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Breast Cancer Res. 2021 Aug 15;23(1):85
pubmed: 34392831
Anal Chem. 2012 Jan 17;84(2):1003-11
pubmed: 22122760
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Transl Oncol. 2020 Feb;13(2):321-328
pubmed: 31877464
Clin Cancer Res. 2014 May 15;20(10):2643-2650
pubmed: 24504125
J Clin Oncol. 2022 Oct 1;40(28):3246-3256
pubmed: 35584336
Cancer Treat Rev. 2017 Jan;52:33-40
pubmed: 27886589
Thorac Cancer. 2019 Oct;10(10):1879-1884
pubmed: 31414729
Sci Rep. 2023 Jan 23;13(1):1258
pubmed: 36690653
PLoS Med. 2016 Dec 27;13(12):e1002201
pubmed: 28027327
Cancer. 2019 Nov 1;125(21):3714-3728
pubmed: 31318440
Breast Cancer Res Treat. 2010 Apr;120(2):461-7
pubmed: 20107891
Transl Res. 2015 Dec;166(6):540-553.e2
pubmed: 26434753
Nature. 2013 May 2;497(7447):108-12
pubmed: 23563269
Mod Pathol. 2018 Jan;31(1):56-61
pubmed: 28799536
Oncology (Williston Park). 2012 Aug;26(8):688-94, 696
pubmed: 22957400
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Nat Commun. 2016 May 13;7:11579
pubmed: 27174596
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
J Clin Oncol. 2016 Sep 1;34(25):2961-8
pubmed: 27269946
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
pubmed: 10430926
Clin Chem. 2013 Dec;59(12):1691-3
pubmed: 24100808
J Natl Cancer Inst. 2009 Sep 16;101(18):1284-5
pubmed: 19641175
Sci Transl Med. 2015 Nov 11;7(313):313ra182
pubmed: 26560360
Iran J Cancer Prev. 2016 Aug 13;9(4):e6565
pubmed: 27761212
Clin Biochem. 2013 Oct;46(15):1561-5
pubmed: 23769817
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Onco Targets Ther. 2015 Nov 11;8:3323-8
pubmed: 26648736
Cancer Treat Res Commun. 2019;19:100123
pubmed: 30826563
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:220-34
pubmed: 26455641
Clin Biochem. 2015 Oct;48(15):948-56
pubmed: 25828047
Mol Oncol. 2016 Mar;10(3):464-74
pubmed: 26776681
Cancer Discov. 2017 Mar;7(3):277-287
pubmed: 27986707
Breast Cancer Res Treat. 2017 Jun;163(2):231-240
pubmed: 28283903
Sci Rep. 2019 Jul 18;9(1):10426
pubmed: 31320709
Breast Cancer Res. 2020 Feb 3;22(1):16
pubmed: 32014063
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Nat Med. 2015 Jul;21(7):751-9
pubmed: 26099045
Int J Cancer. 2008 Mar 1;122(5):1089-94
pubmed: 17960621
N Engl J Med. 2013 Feb 28;368(9):842-51
pubmed: 23445095
Clin Chem. 2015 Jul;61(7):974-82
pubmed: 25979954
Front Oncol. 2020 Dec 15;10:587671
pubmed: 33384956
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315
pubmed: 31647985
Future Oncol. 2023 Mar;19(8):559-573
pubmed: 37070653
Nat Commun. 2018 Mar 1;9(1):896
pubmed: 29497091
Ann Oncol. 2021 Apr;32(4):488-499
pubmed: 33385521
Clin Chem. 2015 Jan;61(1):112-23
pubmed: 25388429
JAMA Oncol. 2016 Oct 01;2(10):1310-1315
pubmed: 27532364
Clin Cancer Res. 2020 Oct 1;26(19):5172-5177
pubmed: 32546646
Arch Pathol Lab Med. 2017 Nov;141(11):1544-1557
pubmed: 28782984
Sci Transl Med. 2012 May 30;4(136):136ra68
pubmed: 22649089
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083
Oncotarget. 2016 Nov 15;7(46):74448-74459
pubmed: 27801670
Oncotarget. 2018 Apr 20;9(30):21122-21131
pubmed: 29765524
Clin Chem. 2013 Jan;59(1):110-8
pubmed: 23014601